Study #2024-1323
A phase 1b/2, open-label, master protocol study of BTK-degrader BGB-16673 in combination with other agents in patients with relapsed or refractory B-cell malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
BGB-16673, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab, Obinutuzumab
Description
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
Study phase:
Physician name:
Nitin Jain
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.